Export abgeschlossen — 

Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real‐World Practice

Several immune checkpoint inhibitor therapies (CPIs) have been approved to treat metastatic urothelial cell carcinoma (mUC). Because of the favorable toxicity profile of CPI compared with chemotherapy, oncologists may have a low threshold to prescribe CPI to patients near the end of life. We evaluat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncologist
Hauptverfasser: Parikh, Ravi B., Galsky, Matthew D., Gyawali, Bishal, Riaz, Fauzia, Kaufmann, Tara L., Cohen, Aaron B., Adamson, Blythe J.S., Gross, Cary P., Meropol, Neal J., Mamtani, Ronac
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley & Sons, Inc. 2019
Schlagworte:
Brief Communications
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656487/
https://ncbi.nlm.nih.gov/pubmed/30944183
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0039
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge